A phase II, biomarker study using digital PCR method in EGFR mutated, advanced lung adenocarcinoma patients treated with afatinib. WJOG8114LTR

Trial Profile

A phase II, biomarker study using digital PCR method in EGFR mutated, advanced lung adenocarcinoma patients treated with afatinib. WJOG8114LTR

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Afatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 18 Oct 2017 Update results presented at the 18th World Conference on Lung Cancer.
    • 20 Apr 2016 Trial design presented at the 107th Annual Meeting of the American Association for Cancer Research
    • 04 Dec 2015 Status changed from recruiting to active, no longer recruiting, as reported by University Medical Information Network-Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top